中国科技论文统计源期刊 中文核心期刊
美国《化学文摘》《国际药学文摘》
《乌利希期刊指南》
WHO《西太平洋地区医学索引》来源期刊
日本科学技术振兴机构数据库（JST）
第七届湖北十大名刊提名奖
美国《化学文摘》《国际药学文摘》
《乌利希期刊指南》
WHO《西太平洋地区医学索引》来源期刊
日本科学技术振兴机构数据库（JST）
第七届湖北十大名刊提名奖
The treatment of advanced lung cancer has entered the era of new immunotherapy represented by immunological checkpoint inhibitors (ICIs). Immunotherapy for advanced lung cancer not only covers all pathological types, but has also been approved for a large number of indications throughout the world. However, there are still many unresolved issues in this area. Finding suitable biomarker, paying attention to the characteristics of special population, exploring the best combination therapy mode, and studying the pathological and immunological features, are the key development directions in the field of advanced lung cancer immunotherapy.
The high mortality and poor prognosis of malignant melanoma make it a serious threat to human health.With the rapid development of basic immunology and tumor biology,the immunotherapy of malignant melanoma is entering a new era,immunotherapy for the occurrence, development, invasion and metastasis of malignant melanoma is entering a new stage, and the survival of melanoma patients has been significantly improved.At present, immunotherapy mainly focuses on the combination of PD-1 monoclonal antibody, CTLA-4 monoclonal antibody and immunotherapy.Pembrolizumab, Nivolumab, Ipilimumab used alone, Nivolumab in combination with Ipilimumab and Talimogene laherparepvec have been proven to be effective and safe and have been approved by the FDA for the treatment of malignant melanoma.This article will review the latest advances in immunotherapy drugs and discuss their prospects and challenges.
Immune checkpoint inhibitors (ICIs) have showed dramatic effect in the treatment of advanced malignancies, meanwhile a series risk of immune-related adverse events (irAEs) are caused by ICIs. For the management on monitoring, grade, treatment of irAEs, Europe, the United States and China have made their own guidelines, but there are still many topics that are not covered or controversial in this field. In this review, we will discuss some considerations about the category, mechanism, treatment and biomarkers of irAEs.
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world,especially in China. 70%-80% of patients are diagnosed at advanced stage and can only receive palliative care. Sorafenib has been the standard drug for the treatment of HCC for 10 years, and FOLFOX4, a systematic chemotherapy regimen, has been recommended as a guideline for HCC in China. However, all approved systemic therapies still unsatisfied with limited objective response rates and poor overall survival.The application of immune checkpoint inhibitors in many solid tumors opens up a new prospect of systemic therapy. Immune checkpoint pathway molecules play an important role in the occurrence and development of viral hepatitis, liver cirrhosis and liver cancer, and are also one of the resistance mechanisms of Sorafenib in the treatment of failed HCC on September 23, 2017, FDA approved the application of Nivolumab in HCC based on the results of phase I/II clinical study, marking the arrival of a new era of HCC immunotherapy.
Although malignant tumors have entered into the era of immunotherapy, immunotherapy for breast cancer has been difficult. With the publication of the Phase III IMpassion 130 study at the end of 2018 at the Eurapean Society of Medical Oncology (ESMO) annual meeting, the immune era of breast cancer has begun At present, immunotherapy research on breast cancer mainly focuses on vaccines, chimeric antigen receptor-engineered T cells (CAR-T) treatment and immune checkpoint inhibitors (ICIs). How to reasonably select the population and treatment mode is the key development direction in the field of breast cancer immunotherapy in the future.
The flavor of radix aconite is symphonic, bitter, hot and extremely poisonous; The meridians of the heart, liver, kidney and spleen; Main treatment dispel wind dehumidification, warm through pain. In this paper, the chemical composition and pharmacological action of radix aconite were reviewed based on the data of recent years.In order to provide some reference for clinical medication.
